Online inquiry

IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12979MR)

This product GTTS-WQ12979MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12979MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7325MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ1022MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ5831MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ12883MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ9650MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ7035MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ770MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ2064MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW